CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, announced today that it will present new clinical data and research updates at Cure SMA's Annual SMA Research & Clinical Care Meeting being held June 24-26, 2026, in Orlando,.

businesswire.com - 2026-06-22 08:00:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 134,345 shares of its common stock to eleven newly hired employees, consisting of inducement stock options to purchase an aggregate of 50,936 shares of common stock and inducement restricted stock units, covering an aggregate of 83,409 shares of its common stock. The awards are subject to all terms and conditions and other provi.

businesswire.com - 2026-06-12 16:15:00

Scholar Rock Holding Corporation (SRRK) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 12:32:14

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9, 2026 at 10:.

businesswire.com - 2026-05-26 09:30:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m.

businesswire.com - 2026-05-20 08:00:00

Eli Lilly (NYSE:LLY | LLY Price Prediction) is the stock everyone wants to talk about, and the reasons are obvious: Mounjaro revenue jumped 125% to $8.66 billion last quarter, the company raised full-year revenue guidance to $82 to $85 billion, and the market cap now sits at roughly $881.8 billion.

247wallst.com - 2026-05-18 13:55:07

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 12,061 shares of common stock and inducement restricted stock units, covering an aggregate of 26,420 shares of its common stock. The awards are subject to all terms and conditions and other provision.

businesswire.com - 2026-05-15 16:15:00

Scholar Rock Holding Corporation (SRRK) Presents at Bank of America Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-05-12 14:20:48

Scholar Rock NASDAQ: SRRK said the U.S. Food and Drug Administration has accepted for review its resubmitted Biologics License Application for apitegromab, the company's investigational treatment for children and adults with spinal muscular atrophy, and set a PDUFA action date of Sept. 30, 2026.

marketbeat.com - 2026-05-08 22:06:20

Scholar Rock Holding Corporation (SRRK) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-07 15:01:27

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today reported financial results for the first quarter ended March 31, 2026, and provided an update on recent company developments. “With the FDA's acc.

businesswire.com - 2026-05-07 07:00:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas, NV, on May 12, 2026 at 8:00 a.m. PT / 11:.

businesswire.com - 2026-04-29 08:00:00

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) COO Keith Woods sold 10,220 shares of the business's stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total value of $506,605.40. Following the completion of the transaction, the chief operating officer directly owned 620,055

defenseworld.net - 2026-04-21 05:02:44

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) CFO Vikas Sinha sold 10,410 shares of the stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $49.57, for a total value of $516,023.70. Following the completion of the transaction, the chief financial officer owned 619,856 shares of

defenseworld.net - 2026-04-21 05:02:43

Scholar Rock Holding Corporation (NASDAQ: SRRK - Get Free Report) insider Akshay Vaishnaw sold 12,246 shares of Scholar Rock stock in a transaction on Thursday, April 16th. The stock was sold at an average price of $49.57, for a total transaction of $607,034.22. Following the sale, the insider directly owned 630,542 shares of the company's stock,

defenseworld.net - 2026-04-21 05:02:43

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 89,304 shares of its common stock to nine newly hired employees, consisting of inducement stock options to purchase an aggregate of 38,331 shares of common stock and inducement restricted stock units, covering an aggregate of 50,973 shares of its common stock. The awards are subject to all terms and conditions and other provisio.

businesswire.com - 2026-04-17 16:15:00

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the financial markets open. The Company will host a conference call and webcast with Scholar Rock management at 8:00 a.m. ET. To access the live audio webcast, please go to “Events and Presentations” in the Investors section of the Scholar Rock website at http://investors.scholarrock.com. To participate via telephone, please reg.

businesswire.com - 2026-04-16 08:00:00